Grants and Contributions:

Back to search

Title:

Value Engineered Translation for Healthcare and Biotechnology Industry

Agreement Number:

915674

Agreement Value:

$37,800.00

Agreement Date:

Nov 15, 2018 - Dec 31, 2019

Description:

Clinical adoption of cell-based treatments is hampered due to the complexity of cell and tissue based therapies compared with small molecules and other drugs, uncertainty in treatment outcomes, a cautious and evolving regulatory process, and lack of proven models of transnational research. We have previously developed an innovative multidisciplinary decision model and value of information analysis framework for cell-based immunotherapies to guide investment decisions in regenerative medicine and inform emerging regulatory frameworks.The goal is to target all manufacturing models of cell-based therapies (autologus and allogeneic) which have proven difficult to successfully translate into marketable product.

Organization:

National Research Council Canada

Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Location:

Edmonton, Alberta, CA T5J 4P6

Reference Number:

172-2018-2019-Q3-915674

Agreement Type:

Contribution

Report Type:

Grants and Contributions

Recipient Business Number:

742088685

Recipient Type:

For-profit organization

Additional Information:

This agreement has been amended 2 time(s). The end date of this agreements has been modified by 77 days.

Amendment Date

Feb 14, 2019

Recipient's Legal Name:

RAZn Health Decision Modelling Ltd.

Federal Riding Name:

Edmonton Centre

Federal Riding Number:

48014

Program:

Industrial Research Assistance Program – Contributions to Firms

Program Purpose:

Coverage:

IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.

NAICS Code:

541330

Amendments:

See Amendments